oral tablet-Hossam Ahmed Abd Ellah-postpartum hypertension

This entry refers to the oral antihypertensive medications, specifically **nifedipine** and **labetalol**, evaluated in a Phase 4 clinical trial (NCT04340232) sponsored by Hossam Ahmed Abd Ellah for the treatment of persistent postpartum hypertension. Nifedipine is a dihydropyridine calcium channel blocker that induces vasodilation by inhibiting calcium influx into vascular smooth muscle through L-type channels. Labetalol is a mixed alpha/beta-adrenergic antagonist that reduces blood pressure by decreasing systemic vascular resistance and heart rate. The trial aims to compare the efficacy and safety of these two standard-of-care oral treatments in managing elevated blood pressure following delivery, a critical period for preventing maternal morbidity such as stroke or eclampsia.

Other names

Oral Tabletnifedipinelabetalol